Meeting
2018 Gastrointestinal Cancers Symposium
Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.
Authors
Madiha Naseem
USC Keck School of Medicine, Los Angeles, CA
Madiha Naseem , Martin D Berger , Alberto Puccini , Ryuma Tokunaga , FRANCESCA BATTAGLIN , Afsaneh Barzi , Shivani Soni , Michelle McSkane , Shu Cao , Joshua Millstein , Wu Zhang , Fotios Loupakis , Sebastian Stintzing , Volker Heinemann , Alfredo Falcone , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 662)
DOI
10.1200/JCO.2018.36.4_suppl.662
Abstract #
662
Poster Bd #
E23
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.
First Author: Madiha Naseem
Poster
2021 Gastrointestinal Cancers Symposium
Single nucleotide polymorphisms (SNPs) in endoplasmic reticulum (ER) stress response genes to predict first-line treatment outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from the MAVERICC and FIRE-3 trials.
First Author: Francesca Battaglin
Poster
2021 Gastrointestinal Cancers Symposium
Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.
First Author: Jingyuan Wang
Poster
2019 Gastrointestinal Cancers Symposium
Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.
First Author: Francesca Battaglin